Breast Cancer Association Consortium; Dorling L et al. Breast cancer risk genes — Association analysis in more than 113,000 women. N Engl J Med 2021;384(5):428-39. Abstract

Desai NV et al. Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years. Cancer 2021;127(6):828-33. Abstract

Hu C et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021;384(5):440-51. Abstract

Litton JK et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. ASCO 2021;Abstract 505.

Litton JK et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753-63. Abstract

Miller RE et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020;31(12):1606-22. Abstract

Pilié PG et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16(2):81-104. Abstract

Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523-33. Abstract

Tung NM et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 2020:38(36):4274-82. Abstract

Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022.

Yadav S et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 2020;38(13):1409-18. Abstract